The goliath retail pharmacy company is replacing General Electric in a key stock market index.
Rumors are flying that big pharma could make a bid for Tesaro.
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
CVS Health is introducing a new service that's got investors seeing green.
The company's being acquired by long-time partner Roche Holdings.
The FDA has dealt the company some disappointing news on one of its late-stage drugs.
A disappointing setback in a key clinical trial has investors scurrying for the exit.
The company announced positive news for one of its most advanced RNAi therapies in development.
Here's how much money the average married couple is receiving in Social Security benefits this year.
Social Security's on shaky financial ground and a big cut to benefits is on the horizon.
Celgene's fallen out of favor with investors, but drugs currently in development might make buying its shares smart.
Here's how this small medical device company is helping to tackle diabetes and why it might be worth buying in your portfolio.
Social Security’s earnings test means that you could end up with less in benefits if you’re not prepared.
Understanding Social Security's average indexed monthly earnings calculation is important if you want to know how much money you can receive in Social Security income.
A potential blockbuster drug is expected to have pivotal data available soon.
Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.
Declining sales increase the stakes for Gilead's most-promising R&D projects.
There are thousands of publicly traded stocks, but I settled on adding these three to my portfolio this month.
The surprise departure of its long-time CEO and the recent approval of two new drugs have investors wondering if a deal is coming.
Mylan's latest FDA approval puts it in direct competition against one of Amgen's most important drugs.